Skip to main content
. 2024 Jun 18;14:14092. doi: 10.1038/s41598-024-64126-0

Figure 6.

Figure 6

Expression of β-catenin and PD-L1 following administration of PAK4 inhibitor in oral squamous cell carcinoma (OSCC) tumour-bearing mice. In OSCC tumour-bearing mice administered the PAK4 inhibitor, PF-3758309, the expression of β-catenin in tumour cells and of PD-L1 on the surface of tumour cells was analysed using flow cytometry. Representative histograms and bar graph of overall results are shown (n = 4/group); p < 0.05, control versus PF-3758309. Numbers in each panel indicate the mean fluorescence intensity of each molecule in control (upper value) and PAK4 inhibitor-treated (lower value) mice.